Orphi Therapeutics Inc
Biotech · Acquired
OT1009, a small molecule pharmacological chaperone that stabilizes β-hexosaminidase to treat GM2 gangliosidoses (Tay-Sachs and Sandhoff disease)
- Grants
- $3.7M
- 7 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20142015201620172018
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Pharmacological Chaperone Therapy for the GM2 Gangliosidoses | $149,681 | |
| Federal grant | Department of Health and Human Services · Phase I · Pharmacological Chaperone Therapy for the GM2 Gangliosidoses | $149,681 | |
| Federal grant | Department of Health and Human Services · Phase I · Optimization and Lead Selection of an Iminosugar Pharmacological Chaperone for the Treatment of Alzheimer's Disease | $224,914 | |
| Federal grant | Department of Health and Human Services · Phase I · Optimization and Lead Selection of an Iminosugar Pharmacological Chaperone for the Treatment of Alzheimer's Disease | $224,914 | |
| Federal grant | Department of Health and Human Services · Phase II · Pharmacological Chaperone Therapy for the GM2 Gangliosidoses | $860,232 | |
| Federal grant | Department of Health and Human Services · Phase II · Pharmacological Chaperone Therapy for the GM2 Gangliosidoses | $1,494,785 | |
| Federal grant | Department of Health and Human Services · Phase II · Pharmacological Chaperone Therapy for the GM2 Gangliosidoses | $634,553 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1674 | PHOTOCHEM TECHNOLOGIES, LLC | — | — |
| 1675 | Deep Creek Pharma, LLC | — | — |
| 1676 | Cubist Pharmaceuticals | — | — |
| 1677 | Orphi Therapeutics Inc | — | — |
| 1678 | Myovant Sciences | — | — |
| 1679 | ROKE BIOTECHNOLOGIES LLC | — | — |
| 1680 | MANDALMED, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.